Our Team
Robert K. Schultz, Ph.D.
Co-Founder & Chief Executive Officer
Robert K. Schultz, Ph.D., is a biomedical entrepreneur and executive with more than four decades of experience developing pharmaceuticals, medical devices, and drug–device combination technologies. His career has focused on translating complex scientific innovations into clinically practical medical products while building organizations capable of executing capital-efficient development programs.
Dr. Schultz previously served as President and Chief Operating Officer of REVA Medical, where he led the development of a novel radiopaque bioresorbable coronary scaffold platform combining proprietary biodegradable polymer technology with drug-eluting capability. The program addressed complex challenges at the intersection of materials science, drug delivery, and vascular device engineering, and advanced through international clinical development and regulatory approval in Europe.
In addition to leading product development, Dr. Schultz has extensive executive leadership experience, including strategic planning, financing, and operational execution. He has worked closely with boards and investors to secure venture and strategic funding, translate corporate strategy into focused development plans, and build organizations capable of delivering complex programs under resource-constrained conditions. He has repeatedly led teams to execute challenging development programs requiring disciplined prioritization and rapid problem-solving.
Throughout his career, Dr. Schultz has worked across polymer science, device engineering, pharmacology, and clinical development, with experience spanning both pharmaceutical and medical device regulatory pathways. He has collaborated with leading academic institutions to in-license and develop novel technologies and has a proven track record of building and leading multidisciplinary teams—both internally and through external CRO partnerships—to advance technologies through preclinical and clinical development toward regulatory submission in the United States and Europe.
As Co-Founder and Chief Executive Officer of SJC Bio, Dr. Schultz leads the development of OsseoCem, applying his experience at the intersection of science, engineering, and executive leadership to advance a new class of structural regenerative biomaterials for dental surgery.
Steven Schneider, DDS, MBA
Co-Founder & Chief Dental Officer
Steven J. Schneider, DDS, MBA, is a nationally recognized clinician, entrepreneur, and innovator with more than four decades of experience in dental practice, product development, and business leadership.
Dr. Schneider operates a leading private practice in San Diego and has been recognized among America’s Top 100 Dentists and San Diego’s Best Dentist. Over nearly 40 years of clinical experience, he has performed a broad range of procedures including implant placement, restorative dentistry, TMJ treatment, and sleep apnea therapy, providing him with deep insight into the practical challenges of dental surgery and patient care.
In addition to his clinical work, Dr. Schneider has a long history of developing and commercializing dental technologies. He has developed multiple dental products, including the Schneider Appliance occlusal guard and an intra/extra oral composite curing system, which were successfully licensed to industry partners. He has also served as a consultant and beta tester for leading dental companies, contributing to the development, clinical validation, and adoption of new materials and technologies.
Dr. Schneider is an internationally recognized speaker on dental materials, clinical techniques, and practice management, and has worked extensively with clinicians and industry partners to advance innovation in dental care.
He has a proven ability to translate clinical insight into practical product solutions and to guide development toward real-world adoption, ensuring that new technologies integrate seamlessly into existing dental workflows.
As Co-Founder and Chief Dental Officer of SJC Bio, Dr. Schneider provides clinical leadership for the development of OsseoCem. His experience ensures that the technology addresses critical unmet needs in implant dentistry and is positioned for successful adoption by clinicians.